How can behavioral modifications help manage lower urinary tract symptoms (LUTS)?

Behavioral modifications, such as regulating the timing and type of fluid intake, are the first step. For example, avoiding diuretics like caffeine and excessive fluids before bed can reduce nighttime urination. Voiding diaries can help men understand their fluid intake and urination patterns to make informed changes.

What are the common pharmacologic treatments for LUTS?

First-line pharmacologic treatments include alpha-blockers like Alfusin or Rapaflo, which relax smooth muscles in the prostate to improve urinary flow. For 'storage' symptoms like frequency and urgency, M3 agonists are used to relax bladder muscles, offering a cleaner profile than older antimuscarinics.

What is the HoLEP procedure, and how does it compare to a traditional TURP?

HoLEP (Holmium Laser Enucleation of the Prostate) is a minimally invasive surgical procedure that removes the entire enlarged prostate pulp in one piece, offering durable results and quicker recovery with fewer catheters post-procedure. A traditional TURP (Transurethral Resection of the Prostate) scrapes out small chunks of tissue at a time, often leading to more bleeding and a longer recovery.

What is chronic pelvic pain syndrome (CPPS), and how is it diagnosed and treated?

CPPS is a constellation of pelvic pain and discomfort without a clear bacterial infection. Diagnosis can involve the Stamey four-glass test to rule out infection. Treatment focuses on identifying the source, which can be inflammation or pelvic floor muscle tightness. Myofascial release or anti-inflammatory medications are often used.

Can dehydration in older adults lead to life-threatening urinary tract infections?

Yes, older adults, especially those with cognitive impairment, may not experience thirst effectively. This can lead to concentrated urine, making them more susceptible to severe urinary tract infections and potentially lethal conditions like urosepsis. Good hydration and hygiene are crucial for prevention.

What is Post-Finasteride Syndrome (PFS) and its prevalence?

PFS is a controversial syndrome where men experience persistent sexual, neurological, and physical side effects after stopping finasteride or dutasteride. Symptoms include decreased sex drive, impotence, anejaculation, and depression. Its prevalence is debated but estimated to affect 5-15% of users, with some cases being permanent.

How do testosterone and dihydrotestosterone (DHT) influence prostate cancer?

Prostate development and growth are highly sensitive to androgens like testosterone and DHT. While high levels in youth don't cause cancer, the ratio of testosterone to estrogen and epigenetic changes throughout life can set the stage for cancer. Aggressive prostate cancers can thrive in low-testosterone environments.

How is the PSA blood test used as a screening tool for prostate cancer, and what are its limitations?

The PSA test measures prostate-specific antigen, which leaks from prostate cells into the bloodstream. It's a powerful tool but not cancer-specific, meaning elevated levels can be due to BPH or inflammation. Refined values like percent free PSA and PSA density, combined with age-adjusted medians, improve its diagnostic accuracy and help determine the need for further evaluation.

What role does MRI play in modern prostate cancer diagnosis before a biopsy?

MRI, particularly a 3T multiparametric MRI, is crucial before a prostate biopsy. It provides a high-resolution map of the prostate to identify suspicious lesions (rated by PI-RADS score) and helps direct biopsies, reducing unnecessary procedures and improving detection of clinically significant cancers.

What is the Gleason Score, and how does it determine treatment for prostate cancer?

The Gleason Score grades prostate cancer based on the cellular patterns observed in a biopsy. Scores range from 6 (least aggressive) to 10 (most aggressive). A Gleason 6 may be safely monitored with active surveillance, while higher scores, especially with a significant percentage of Pattern 4 tissue, usually require active treatment such as surgery or radiation.

What is active surveillance for Gleason 6 prostate cancer?

Active surveillance involves closely monitoring low-volume, low-grade Gleason 6 prostate cancer with regular PSA tests, prostate MRIs, and confirmatory biopsies. This approach avoids immediate treatment and its side effects, as these cancers often have low lethal potential and may not require aggressive intervention initially.

What are the latest advancements in radiation therapy for prostate cancer?

Recent advancements include hydrogel (SpaceOAR) placement to separate the prostate from the rectum, reducing rectal side effects. MRI-guided linear accelerators offer real-time adjustment of radiation beams for extreme precision, minimizing damage to surrounding tissues and allowing for boosting specific tumor lesions.

How has prostatectomy evolved, and what is 'pelvic fascial sparing surgery'?

Prostatectomy has evolved from open, highly morbid procedures to robotic-assisted techniques. Pelvic fascial sparing surgery is an advanced robotic technique that preserves the fascia, ligaments, and nerves surrounding the prostate. This significantly improves functional outcomes like continence and erectile function while still achieving excellent cancer control.

Key Moments

273 ‒ Prostate health: common problems, cancer prevention, screening, treatment, and more

Peter Attia MD

Science & Technology6 min read227 min video

Oct 2, 2023|979,428 views|5,101|430

Peter Attia MD Dr. Peter Attia Early Medical The Drive Podcast The Drive Longevity Zone 2

Save to Pod

Key Moments

On this page

TL;DR

Comprehensive guide to prostate health: addressing common issues, cancer detection, and advanced treatments.

Key Insights

Prostate issues are common with age, impacting urinary function; behavioral changes and specific medications are first-line treatments.

Advanced surgical techniques, like HOLEP, offer highly effective and less invasive solutions for benign prostatic hyperplasia (BPH).

PSA testing, despite its controversy, remains a vital screening tool for prostate cancer, especially when combined with advanced metrics and MRI.

Prostate cancer biology is complex; distinguishing between luminal and basal-like tumors is crucial for personalized treatment, with basal-like tumors being more aggressive.

Androgen deprivation therapy (ADT) is a cornerstone of advanced prostate cancer treatment, effectively extending life, but newer agents and multimodal approaches offer greater efficacy and potentially reduced side effects.

Post-finasteride syndrome, though debated in frequency, represents significant and sometimes irreversible side effects for a subset of men taking 5-alpha reductase inhibitors.

Understanding the Prostate and Common Issues

The prostate, an exocrine gland unique to men, is integral to the reproductive system, situated below the bladder. It produces 50-60% of seminal fluid. As men age, it commonly presents with issues like prostatitis (inflammation, often difficult to diagnose), benign prostatic hyperplasia (BPH), and prostate cancer. BPH leads to lower urinary tract symptoms (LUTS) like weak stream, urgency, and frequency due to prostatic enlargement compressing the urethra and thickening the bladder wall. By age 50, 50-60% experience LUTS, rising to 75-80% by age 60.

Medical and Behavioral Management of LUTS

Initial management for LUTS involves behavioral modifications, such as regulating fluid intake, timing of consumption (avoiding drinks before bed), and limiting diuretics like caffeine. Voiding diaries help patients understand input/output patterns. Pharmacologically, alpha-blockers like alfuzosin or silodosin are first-line, relaxing prostate smooth muscle to improve urine flow with fewer sexual side effects than older generations. M3 agonists or antimuscarinics treat storage symptoms (frequency, urgency) by relaxing the bladder, with newer M3 agonists being safer for cognitive function than older antimuscarinics, which can worsen dementia.

Surgical Interventions for BPH

When medical management fails, surgical options become viable. The transurethral resection of the prostate (TURP) is the historical gold standard, now a bipolar TURP using saline to prevent hyponatremia. Newer minimally invasive techniques include steam ablation (Rezūm) and UroLift (suspending the urethra), though these offer less durable relief. Holmium laser enucleation of the prostate (HOLEP) is a highly effective procedure, capable of removing the entire hypertrophied adenoma (pulp of the orange) in one piece, offering lasting relief with shorter catheter times and less bleeding, even for very large prostates.

Anatomy, Hormones, and Prostatitis Pathology

The prostate's proximity to the rectum explains how issues like constipation can exacerbate urinary symptoms. Chronic pelvic pain syndrome, often misdiagnosed as bacterial prostatitis, can stem from non-bacterial inflammation or pelvic floor dysfunction. The 'four-glass test' (Stamey test) differentiates urethral, bladder, and prostatic infections. Many cases of chronic pelvic pain, without a clear bacterial cause, respond to anti-inflammatory drugs or myofascial release, even a single prostatic massage can be profoundly effective. Some cases may link to mast cell dysfunction, pointing to varied underlying etiologies.

Prostate Cancer Epidemiology and Risk Factors

Prostate cancer is the second leading cause of cancer death in men (~34,000 deaths annually out of 250,000-260,000 diagnoses), indicating a relatively good diagnosis-to-death ratio compared to other cancers. Risk factors include family history (first-degree relatives like father, uncle, or brother, but not grandfather unless father also affected), age, and certain ancestries (especially West African and Ashkenazi Jewish men). Smoking increases the risk of more aggressive prostate cancer at a younger age. Metabolic syndrome and type 2 diabetes also correlate with increased risk and aggressiveness.

Androgen's Role in Prostate Development and Cancer

Androgens (testosterone and dihydrotestosterone - DHT) are crucial for prostate development and function. Testosterone, converted to the more potent DHT by 5-alpha reductase, binds to androgen receptors, acting as a transcription factor to regulate gene expression. While high testosterone in younger men does not directly cause prostate cancer, the prostate's exposure to androgens throughout life, coupled with epigenetic changes, sets the stage for cancer development. The ratio of testosterone to estrogen (T:E) is believed to influence benign prostatic growth more than cancer development.

Post-Finasteride Syndrome and 5-Alpha Reductase Inhibitors

5-alpha reductase inhibitors (finasteride, dutasteride), used to treat BPH (Proscar) and hair loss (Propecia), block testosterone conversion to DHT. While effective for BPH and hair loss, they can lead to Post-Finasteride Syndrome in a notable percentage of men, characterized by decreased libido, erectile dysfunction, anejaculation, and depression. These side effects can be persistent or irreversible for some. Crucially, these drugs halve PSA levels, potentially masking underlying aggressive prostate cancer, making careful monitoring and patient education paramount when prescribing.

PSA: Detection and Interpretation

Prostate-specific antigen (PSA) is a protein produced by the prostate, liquefying semen. While naturally present in semen, its presence in the blood, measured by a PSA test, indicates leakage from prostate cells. Free PSA (unbound) vs. bound PSA ratios help differentiate benign prostatic conditions from cancer. A higher percentage of free PSA suggests BPH, while lower suggests cancer. Advanced tests, like the 4K score or Prostate Health Index, combine PSA and its variants to better predict aggressive cancer risk. An elevated PSA, especially with high velocity or density, warrants further investigation.

PSA Screening Controversies and Guidelines

Despite criticism, PSA testing is a powerful screening tool. Many medical organizations now recommend informed decision-making conversations between patients and physicians about PSA screening's risks and benefits. National Comprehensive Cancer Network (NCCN) guidelines suggest baseline PSA testing at age 45, with follow-up intervals based on initial levels. The historical argument against widespread PSA testing (overdiagnosis and overtreatment) is mitigated by modern diagnostics that prevent unnecessary biopsies and treatments. Early detection significantly reduces mortality from prostate cancer.

Advancements in Prostate Cancer Diagnostics

Multiparametric MRI (mpMRI), particularly 3T MRI, is now standard before biopsy for men with elevated PSA. It identifies suspicious lesions (graded by PI-RADS scores 3-5), guiding targeted biopsies and reducing unnecessary systematic biopsies by 50%. This improves detection of clinically significant cancers. Transperineal biopsies, performed through the skin between the rectum and scrotum, are gaining traction over transrectal biopsies due to significantly lower infection rates, especially when combined with a prophylactic antibiotic.

Gleason Scoring and Active Surveillance

The Gleason score, assigned by pathologists, describes the pattern of cancer cells, with scores 3-5 reflecting increasing abnormality. Gleason 6 (3+3) is the least aggressive, rarely metastasizes, and is often managed with active surveillance (intensive monitoring). This approach avoids overtreatment and preserves quality of life. Gleason 7 (3+4 or 4+3) involves a blend of patterns, with the percentage of pattern 4 being critical for determining aggressiveness. Higher Gleason scores (8-10) indicate more aggressive cancers requiring immediate and often multimodal treatment.

Treatment for High-Risk and Metastatic Prostate Cancer

High-grade prostate cancers (Gleason 8-10) require aggressive treatment. A PSMA PET scan accurately stages aggressive disease, identifying metastases to lymph nodes or bones. For localized aggressive disease, radical prostatectomy (robotic-assisted) is common, often followed by radiation. For metastatic disease, systemic therapy is necessary. Androgen Deprivation Therapy (ADT) is the cornerstone, using LHRH agonists/antagonists to suppress testosterone. Newer agents like abiraterone (CYP17 inhibitor) and enzalutamide/apalutamide/darolutamide (androgen receptor inhibitors) significantly extend survival, offering a median survival of 7-8 years for newly diagnosed metastatic disease. Radiation is often combined with ADT (as a sensitizer) for localized, high-risk disease, with modern techniques like hydrogel spacers and MRI-guided linear accelerators reducing side effects.

Mentioned in This Episode

●Supplements

●Products

●Software & Apps

●Tools

●Companies

●Organizations

●Drugs & Medications

●Studies Cited

●Concepts

●People Referenced

Prostate Health Management: Dos & Don'ts

Practical takeaways from this episode

Do This

Regulate fluid intake, especially before bed (LUTS management).

Wear knee-high compression stockings if experiencing peripheral edema and nocturia.

Utilize modern alpha-blockers (Alfusin, Rapaflo) for obstructive LUTS symptoms.

Consider M3 agonists for storage LUTS symptoms (frequency, urgency).

Explore HoLEP surgery for BPH if medications fail, especially for large prostates.

Monitor bowel habits for regularity, as constipation can exacerbate pelvic pain and urinary symptoms.

Seek myofascial release for pelvic floor tightness if experiencing chronic pelvic pain syndrome.

Maintain good hydration to prevent concentrated urine, especially in older age.

Get a baseline PSA test at age 45 and track it over time, understanding age-adjusted medians.

Always get a multiparametric MRI before a prostate biopsy if PSA is elevated, unless contraindicated.

Undergo repeated targeted and systematic biopsies if MRI suggests a suspicious lesion (PI-RADS 3-5).

Discuss active surveillance with your physician for low-volume, low-grade Gleason 6 prostate cancer.

For aggressive prostate cancers (Gleason 8+), insist on a PET PSMA scan for accurate staging.

Inquire about pelvic fascial sparing techniques if considering prostatectomy for cancer.

Discuss pre-surgical neuroprotective agents and postoperative care like prostaglandins and penile rehabilitation to aid erectile function recovery.

Ask about your urologist's surgical margin rates and functional recovery outcomes (continence, erectile function).

Look for urologists with a specialized practice focused on prostatectomy for better outcomes.

Embrace precision medicine approaches, including molecular subtyping of tumors for personalized treatment plans.

Avoid This

Drink excessive fluids or diuretics (e.g., caffeine, alcohol) right before going to bed if experiencing nocturia.

Ignore persistent urinary symptoms or pelvic pain, as they can indicate underlying conditions.

Rely solely on older antimuscarinic drugs for LUTS if M3 agonists are available, due to potential cognitive side effects.

Undergo procedures like UroLift if more durable and effective options are available, as they offer only temporary relief and can interfere with MRI scans.

Take finasteride or dutasteride without understanding the potential for Post-Finasteride Syndrome (PFS) or its impact on PSA values and prostate cancer detection.

Assume a rising PSA on finasteride is normal; it's a warning sign for potential aggressive cancer.

Overlook environmental factors like smoking, poor diet, and pollution as contributors to prostate cancer risk.

Dismiss the PSA test as useless; it's a powerful tool when used correctly with other diagnostics.

Forego an MRI before biopsy if not contraindicated, as it significantly improves diagnostic accuracy.

Accept a prostate biopsy that does not systematically sample the prostate or target suspicious MRI lesions.

Rush into radical treatment for low-volume, low-grade Gleason 6 prostate cancer without considering active surveillance.

Assume surgery alone will cure high-grade or locally advanced prostate cancer without considering multimodal therapy.

Neglect the quality of life impacts (sexual, urinary, GI) when choosing between radiation and surgery.

Common Questions

As men age, common LUTS include a weak stream, hesitation or slowness in starting urination, increased urgency, and frequent urination. These symptoms are often related to prostate enlargement compressing the urethra and thickening the bladder wall. By age 60, 75-80% of men experience LUTS.

Topics

Prostate Health Lower Urinary Tract Symptoms Benign Prostatic Hyperplasia PSA Screening Prostatitis Robotic Prostatectomy Finasteride Side Effects Genomic Testing Metastatic Prostate Cancer

Mentioned in this video

Concepts

Nocturia

Frequent nighttime urination, which can be influenced by natural hormonal cycles, fluid intake, and conditions like sleep apnea or peripheral edema.

Human Kallikrein 3 (hk3)

Also known as PSA, a key biomarker. Its measurement, along with related kallikreins, refines prostate cancer risk assessment in advanced PSA tests.

PET PSMA Scan

A specialized PET scan using prostate-specific membrane antigen (PSMA) as a radioligand to detect and stage high-grade prostate cancer, especially useful for metastatic disease.

PSA Density

The ratio of PSA value to prostate volume, used to assess prostate cancer risk and aggressiveness. A higher density generally indicates higher risk.

Antidiuretic Hormone (ADH)

A naturally secreted hormone that prevents diuresis and fluid production, with its nocturnal surge attenuating with age, impacting nighttime urination.

Stamey Four-Glass Test

A diagnostic procedure involving collecting urine in phases and prostatic fluid to accurately determine the source of a urinary tract infection, particularly distinguishing bladder from prostate infection.

3T MRI

A three Tesla MRI, a high-resolution imaging technique used to visualize suspicious lesions in the prostate before biopsy, improving diagnostic accuracy.

Prostate Stimulating Antigen (PSA)

A protein enzyme in semen produced by the prostate, its levels in the blood serve as a biomarker for prostate health and cancer detection.

Prostatitis

Inflammation or infection of the prostate gland, often causing pelvic pain and discomfort.

MRI-guided Linear Accelerator

Advanced radiation therapy equipment that uses real-time MRI guidance to precisely target the prostate and adjust for subtle movements, minimizing damage to surrounding tissues.

Myofascial Release

A physical therapy technique, often transrectal, used to relieve tightness and pain in pelvic floor muscles, effective for some men with chronic pelvic pain syndrome.

BRCA Gene

Genes (BRCA1 and BRCA2) associated with homologous recombination deficiency, increasing risk for breast and prostate cancer. Notably, BRCA2 deficiency is potent for prostate cancer risk.

Lower Urinary Tract Symptoms (LUTS)

A group of symptoms affecting the lower urinary tract, often related to benign prostatic hyperplasia (BPH), including weak stream, urgency, and increased frequency.

PI-RADS (Prostate Imaging Reporting and Data System)

A scoring system from 1 to 5 used by radiologists to categorize the likelihood of clinically significant prostate cancer on multiparametric MRI.

Human Kallikrein 2 (hk2)

A sibling molecule to PSA, also produced in prostatic epithelial cells, used in advanced PSA tests to improve prostate cancer detection.

Free PSA

The amount of PSA in the bloodstream that is not bound to other proteins. A higher percentage typically indicates a benign prostate condition.

Chronic Pelvic Pain Syndrome (CPPS)

A constellation of symptoms including pelvic pain and discomfort, often without clear pathology, can be bacterial, viral, or related to pelvic floor dysfunction.

Post-Finasteride Syndrome (PFS)

A controversial syndrome where men experience symptoms like decreased sex drive, impotence, anejaculation, and depression after discontinuing finasteride or dutasteride.

Drugs & Medications

Alfusin

A third-generation alpha blocker used to treat LUTS, known for less impact on sexual dysfunction and semen production.

Dutasteride (Avodart)

A 5-alpha reductase inhibitor (5ARI) more potent than finasteride in blocking DHT conversion, used for BPH treatment and studied for prostate cancer prevention.

Propecia

A lower-dose formulation of finasteride (1 mg/day) used to treat hair loss.

Finasteride (Proscar)

A 5-alpha reductase inhibitor (5ARI) that blocks the conversion of testosterone to DHT, used to reduce prostate size in BPH and for hair loss (Propecia).

GnRH Antagonists (LHRH Antagonist)

Oral ADT agents that quickly suppress testosterone without an initial surge, allowing for faster testosterone recovery after treatment cessation.

Apalutamide (Erleada)

A novel hormonal therapy that competitively binds to the androgen receptor, used in metastatic prostate cancer, with similar side effects to enzalutamide.

Silodosin (Rapaflo)

A third-generation alpha blocker for LUTS, focusing on prostate relaxation with minimal sexual side effects.

M3 Agonists

A newer class of drugs that relax bladder muscles, effectively treating urinary frequency and urgency with fewer side effects than older antimuscarinics.

GnRH Agonist (LHRH Agonist)

A type of ADT that initially causes a surge in testosterone before shutting down the system, leading to long-term testosterone suppression.

Enzalutamide (Xtandi)

A novel hormonal therapy that is a competitive binder of the androgen receptor, used in metastatic prostate cancer, but can cause side effects like seizures and sleepiness.

Darolutamide (Nubeqa)

The newest novel hormonal therapy in its class, known for being cleaner with less cognitive and seizure side effects due to its poor blood-brain barrier permeability.

Abiraterone (Zytiga)

A CYP17 inhibitor that prevents androgen production not only in the testicles but also in the adrenal glands, leading to deeper testosterone suppression for metastatic prostate cancer.

Alpha Blockers

A class of drugs that relax smooth muscles in the prostate and seminal vesicles, improving urinary symptoms by enhancing the diameter of the prostatic urethra.

People

John Epstein

A researcher at Johns Hopkins who conducted a large study on Gleason 6 prostate cancer, showing no lymph node metastasis.

Charles Huggins

Nobel Prize winner from the University of Chicago whose work established androgen deprivation as a mainstay of prostate cancer therapy.

Eli Vanion

Founder of Decipher, with whom Dr. Schaeffer collaborated on analyzing prostate cancer transcriptomes.

Dr. Amy Cranbeck

A urologist at Northwestern and pioneer in HoLEP surgery, known for her exceptional skill in performing the procedure, especially on large prostates.

Ashley Ross

Brilliant urologist who developed the MYM Risk Calculator, a neural network real-time predictor for prostate cancer risk.

Balentine Carter

At Johns Hopkins, his active surveillance cohort data transformed prostate cancer treatment by demonstrating the safety of monitoring low-risk cancers.

Anthony J. Schaeffer

A scientist at Northwestern University Feinberg School of Medicine, Peter Attia's father and researcher in prostatitis and pelvic pain, focused on mass cell dysfunction.

Chris Hyman

A scientist at USC who published a paper on genomic risk scores and SNPs for prostate cancer, highlighting enrichment in men of African ancestry.

Scott Eggner

A researcher at the University of Chicago who also conducted a large study on Gleason 6 prostate cancer.

Prolactin Tumark

Scientific partner of Dr. Anthony J. Schaeffer at Northwestern, collaborating on research into mass cell dysfunction and pelvic pain.

Software & Apps

4K score

An advanced PSA-based blood test that measures four different kallikrein proteins to assess the risk of aggressive prostate cancer.

MYM Risk Calculator

A neural network real-time predictor developed by Ashley Ross that assesses individual risk for prostate cancer requiring treatment, based on MRI and biopsy data.

Prostate Health Index (PHI)

A mathematical equation that combines total PSA, free PSA, and proPSA to predict the probability of aggressive prostate cancer.

Products

Ted stockings

Knee-high compression stockings used to reduce peripheral edema, which can contribute to nocturnal urinary frequency.

Hydrogel (SpaceOAR)

A percutaneously deposited gel that separates the prostate from the rectum during radiation therapy, reducing rectal side effects.

Companies

Veracyte

A company that owns Decipher, which provides genomic testing for prostate cancer based on transcriptome analysis.

Studies & Research

Mirage Study

A clinical trial conducted at UCLA that demonstrated almost zero rectal side effects from MRI-guided prostate radiation.

Organizations

National Comprehensive Cancer Network (NCCN)

An alliance of cancer centers that publishes guidelines for cancer care, including prostate cancer screening, which are more progressive than other organizations.

Found this useful? Build your knowledge library

Get AI-powered summaries of any YouTube video, podcast, or article in seconds. Save them to your personal pods and access them anytime.

Get Started Free